Hodgkin disease risk: Role of genetic polymorphisms and gene–gene interactions in inflammation pathway genes
- 8 November 2010
- journal article
- research article
- Published by Wiley in Molecular Carcinogenesis
- Vol. 50 (1), 36-46
- https://doi.org/10.1002/mc.20688
Abstract
Inflammation is a critical component of cancer development. The clinical and pathological features of Hodgkin disease (HD) reflect an abnormal immunity that results from cytokines secreted by Reed–Sternberg cells and the surrounding tumor. Numerous studies have reported the association between genetic polymorphisms in cytokine genes and the susceptibility to different hematologic cancers. However, the effects of such SNPs on modulating HD risk have not yet been investigated. We hypothesized that gene–gene interactions between candidate genes in the anti‐ and pro‐inflammatory pathways carrying suspicious polymorphisms may contribute to susceptibility to HD. To test this hypothesis, we conducted a study on 200 HD cases and 220 controls to assess associations between HD risk and 38 functional SNPs in inflammatory genes. We evaluated potential gene–gene interactions using a multi‐analytic strategy combining logistic regression, multi‐factor dimensionality reduction, and classification and regression tree (CART) approaches. We observed that, in combination, allelic variants in the COX2, IL18, ILR4, and IL10 genes modify the risk for developing HD. Moreover, the cumulative genetic risk score (CGRS) revealed a significant trend where the risk for developing HD increases as the number of adverse alleles in the cytokine genes increase. These findings support the notion that epigenetic‐interactions between these cytokines may influence pathogenesis of HD modulating the proliferation of regulatory T cells. In this way, the innate and adaptative immune responses may be altered and defy their usual functions in the host anti‐tumor response. Our study is the first to report the association between polymorphisms in inflammation genes and HD susceptibility risk. Mol. Carcinog.Keywords
This publication has 44 references indexed in Scilit:
- Favorable impact of the interleukin-4 receptor allelic variant I75 on the survival of diffuse large B-cell lymphoma patients demonstrated in a large prospective clinical trialAnnals of Oncology, 2009
- Host immune gene polymorphisms in combination with clinical and demographic factors predict late survival in diffuse large B-cell lymphoma patients in the pre-rituximab eraBlood, 2008
- Molecular epidemiology, cancer-related symptoms, and cytokines pathwayThe Lancet Oncology, 2008
- Association of Single Nucleotide Polymorphisms in the IL-18 Gene with Production of IL-18 Protein by Mononuclear Cells from Healthy DonorsMediators of Inflammation, 2008
- Genetic variation in 1253 immune and inflammation genes and risk of non-Hodgkin lymphomaBlood, 2007
- Joint effect between regular use of non-steroidal anti-inflammatory drugs, variants in inflammatory genes and risk of lymphomaCancer Causes & Control, 2007
- Gene expression shift towards normal B cells, decreased proliferative capacity and distinct surface receptors characterize leukemic blasts persisting during induction therapy in childhood acute lymphoblastic leukemiaLeukemia, 2007
- Interleukin-10 gene promoter polymorphisms influence the clinical outcome of diffuse large B-cell lymphomaBlood, 2004
- MAP Kinase Pathways as a Route for Regulatory Mechanisms of IL-10 and IL-4 Which Inhibit COX-2 Expression in Human MonocytesBiochemical and Biophysical Research Communications, 1998
- A new look at the statistical model identificationIEEE Transactions on Automatic Control, 1974